📊 LMAT Key Takeaways
Is Lemaitre Vascular Inc. (LMAT) a Good Investment?
LeMaitre Vascular demonstrates exceptional financial health with fortress-like balance sheet (zero debt, 12.89x current ratio) and outstanding profitability (71.5% gross margin, 27.2% operating margin). Despite flat revenue, net income surged 31% YoY through operational leverage and strong free cash flow generation of $74.5M (29.8% FCF margin). However, sustained topline growth is critical to validate valuation and operational momentum.
LeMaitre Vascular shows exceptional profitability (71.5% gross, 27.2% operating margin) and a debt-free, highly liquid balance sheet, converting cash efficiently (29.8% FCF margin). Net income and EPS grew ~31% despite flat revenue, indicating mix improvement and operating discipline. The key to sustaining results is reigniting organic growth while preserving margin gains.
Why Buy Lemaitre Vascular Inc. Stock? LMAT Key Strengths
- Exceptional gross margin of 71.5% and operating margin of 27.2% demonstrates pricing power and operational excellence
- Zero long-term debt with 12.89x current ratio and 11.94x quick ratio indicates fortress balance sheet and exceptional liquidity cushion
- Strong free cash flow generation of $74.5M with 29.8% FCF margin demonstrates capital-efficient business model requiring minimal reinvestment
- Debt-free balance sheet with exceptional liquidity
- High and expanding profitability with strong margins
- Robust free-cash-flow generation and low capex needs
LMAT Stock Risks: Lemaitre Vascular Inc. Investment Risks
- Revenue growth completely flat at +0.0% YoY; topline stagnation concerning for medical device sector and unsustainable net income growth trajectory
- Net income growth of 31% is driven by operational leverage on flat revenues, indicating one-time efficiencies or cost-cutting rather than organic growth
- Surgical instruments sector faces intense competitive and pricing pressures that could compress margins without differentiation and innovation pipeline visibility
- Flat revenue growth may cap upside and operating leverage
- Margin gains could normalize amid pricing/reimbursement pressures
- Niche portfolio concentration; growth may rely on new products or M&A execution
Key Metrics to Watch
- Revenue growth acceleration - must return to positive topline growth to sustain valuations
- Gross margin stability - monitor for competitive pricing pressures in medical device market
- Free cash flow sustainability and capital allocation decisions - key indicator of management capital discipline
- Organic revenue growth (YoY)
- Operating margin and FCF margin sustainability
Lemaitre Vascular Inc. (LMAT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 29.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 12.89x current ratio provides a solid financial cushion.
LMAT Profit Margin, ROE & Profitability Analysis
LMAT vs Healthcare Sector: How Lemaitre Vascular Inc. Compares
How Lemaitre Vascular Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lemaitre Vascular Inc. Stock Overvalued? LMAT Valuation Analysis 2026
Based on fundamental analysis, Lemaitre Vascular Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lemaitre Vascular Inc. Balance Sheet: LMAT Debt, Cash & Liquidity
LMAT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lemaitre Vascular Inc.'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.34 reflects profitable operations.
LMAT Revenue Growth, EPS Growth & YoY Performance
LMAT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $47.4M | $6.0M | $0.33 |
| Q2 2024 | $50.1M | $6.0M | $0.36 |
| Q1 2024 | $47.1M | $6.0M | $0.27 |
| Q3 2023 | $39.0M | $3.5M | $0.25 |
| Q2 2023 | $42.1M | $3.5M | $0.16 |
| Q1 2023 | $39.6M | $6.0M | $0.27 |
| Q3 2022 | $38.4M | $3.5M | $0.25 |
| Q2 2022 | $40.7M | $3.5M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lemaitre Vascular Inc. Dividends, Buybacks & Capital Allocation
LMAT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lemaitre Vascular Inc. (CIK: 0001158895)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LMAT
What is the AI rating for LMAT?
Lemaitre Vascular Inc. (LMAT) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LMAT's key strengths?
Claude: Exceptional gross margin of 71.5% and operating margin of 27.2% demonstrates pricing power and operational excellence. Zero long-term debt with 12.89x current ratio and 11.94x quick ratio indicates fortress balance sheet and exceptional liquidity cushion. ChatGPT: Debt-free balance sheet with exceptional liquidity. High and expanding profitability with strong margins.
What are the risks of investing in LMAT?
Claude: Revenue growth completely flat at +0.0% YoY; topline stagnation concerning for medical device sector and unsustainable net income growth trajectory. Net income growth of 31% is driven by operational leverage on flat revenues, indicating one-time efficiencies or cost-cutting rather than organic growth. ChatGPT: Flat revenue growth may cap upside and operating leverage. Margin gains could normalize amid pricing/reimbursement pressures.
What is LMAT's revenue and growth?
Lemaitre Vascular Inc. reported revenue of $249.6M.
Does LMAT pay dividends?
Lemaitre Vascular Inc. pays dividends, with $18.1M distributed to shareholders in the trailing twelve months.
Where can I find LMAT SEC filings?
Official SEC filings for Lemaitre Vascular Inc. (CIK: 0001158895) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LMAT's EPS?
Lemaitre Vascular Inc. has a diluted EPS of $2.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LMAT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lemaitre Vascular Inc. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LMAT stock overvalued or undervalued?
Valuation metrics for LMAT: ROE of 14.7% (sector avg: 15%), net margin of 23.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LMAT stock in 2026?
Our dual AI analysis gives Lemaitre Vascular Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LMAT's free cash flow?
Lemaitre Vascular Inc.'s operating cash flow is $81.3M, with capital expenditures of $6.8M. FCF margin is 29.8%.
How does LMAT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 23.1% (avg: 12%), ROE 14.7% (avg: 15%), current ratio 12.89 (avg: 2).